knowledge -WSS

knowledge

author：explore 2025-10-06 07:54:59 - browse：247

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： National panel will explore requiring free Covid tests

focus

knowledge

WSS

Why psychiatrists like me stop taking insurance

NIH launches clinical trials and new research office for long Covid

Feng Zhang, Grail founder join forces on new gene editing startup

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Mega Millions pot grows to $1.25 billion after no winner

Infectious disease expert Jeanne Marrazzo assumes Fauci role

entertainment

knowledge

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Why psychiatrists like me stop taking insurance

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Morgan Health, with ambitious aims, wants you to know it’s still here

Medical records are filled with copy

AdventHealth escalates lawsuit against insurance vendor Multiplan

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sage hopes for a blockbuster in antidepressant now before FDA

Bright Health sells Medicare Advantage business to Molina

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

explore

Antibiotic resistance and the global rise in human conflict

EQRx, failed developer of low

3 trends to watch in health tech's hiring outlook for 2024

White House finalizes ITC's import ban of latest Apple Watches

Feng Zhang CRISPR delivery startup lays off quarter of staff

Antibiotic resistance and the global rise in human conflict

focus

Wikipedia

knowledge

focus